Compare · JNJ vs PROC
JNJ vs PROC
Side-by-side comparison of Johnson & Johnson (JNJ) and Procaps Group S.A. (PROC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and PROC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $573.71B, about 545.0x PROC ($1.05B).
- JNJ has hit the wire 12 times in the past 4 weeks while PROC has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 0 for PROC).
- Company
- Johnson & Johnson
- Procaps Group S.A.
- Price
- $238.31-0.09%
- $1.16-27.50%
- Market cap
- $573.71B
- $1.05B
- 1M return
- +6.23%
- -
- 1Y return
- +52.12%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Procaps Group S.A.
Procaps Group, S.A. develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and clinical solutions. It operates in 13 countries in Latin America. The company was founded in 1977 and is based in Luxembourg City, Luxembourg
Latest JNJ
- SEC Form 4 filed by Director Woods Eugene A.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Latest PROC
- SEC Form 6-K filed by Procaps Group S.A.
- SEC Form 6-K filed by Procaps Group S.A.
- Procaps Group Receives Delisting Notice From Nasdaq
- SEC Form 6-K filed by Procaps Group S.A.
- SEC Form 6-K filed by Procaps Group S.A.
- Procaps Group Receives Additional Delinquency Letter
- SEC Form 6-K filed by Procaps Group S.A.
- SEC Form 6-K filed by Procaps Group S.A.
- Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
- Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.